| Virology Journal | |
| Characterization of antiviral resistance mutations among the Eastern Indian Hepatitis B virus infected population | |
| Runu Chakravarty1  Sekhar Chakrabarti3  Binay Krishna De2  Avik Biswas1  Rajesh Panigrahi1  | |
| [1] ICMR Virus Unit, Kolkata, ID & BG Hospital Campus, Kolkata, India;Department of Medicine, Calcutta Medical College, Kolkata, West Bengal, India;National Institute of Cholera and Enteric Diseases, Kolkata, India | |
| 关键词: Eastern India; Drug-naïve patients; Drug resistance; HBV infection; | |
| Others : 1151681 DOI : 10.1186/1743-422X-10-56 |
|
| received in 2012-05-14, accepted in 2013-01-14, 发布年份 2013 | |
PDF
|
|
【 摘 要 】
Background
Antiviral therapy using nucleos(t)ide analogues (NAs) is an effective control measure of chronic hepatitis B virus (HBV) infection; however they need long term treatment. Presence of drug-resistance mutations may get in the way of the efficacy of antiviral therapy. Our study was aimed at defining the prevalence of HBV drug-resistance in HBVrt region in a population of 147 HBsAg positive patients.
Findings
HBV/D has shown multiple types of HBVrt mutations both among treatment naïve (65.0%, 13 of 20 HBV/D) and treated patients (56.2%, 9 of 16 HBV/D). In additional, several mutations, with a suggested role in drug resistance, were detected among the treatment naïve as well as the treated patients. The mutations reported to be involved in reduction of drug effectiveness, was common among non-responders to therapy as well as among the naïve patients. Notably, classical antiviral resistance mutations (rtL80I/V-rtI169T-rtV173L-rtL180M-rtA181T/V/S-rtT184A/S/G/C-rtA194T-rtS202C /G/I -rtM204V/I-rtN236T-rtM250V) were not detected.
Conclusion
The prevalence of putative NAr mutations among non responders to therapy suggests that they might have role in reduced efficacy of currently available antivirals and requires further investigations.
【 授权许可】
2013 Panigrahi et al.; licensee BioMed Central Ltd.
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| 20150406093951458.pdf | 484KB | ||
| Figure 1. | 166KB | Image |
【 图 表 】
Figure 1.
【 参考文献 】
- [1]Locarnini S, Mason WS: Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006, 44:422-431.
- [2]Ntziora F, Paraskevis D, Haida C: Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology. J Clin Microbiol 2009, 47:2544-2550.
- [3]Pastor R, Habersetzer F, Fafi-Kremer S: Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients. World J Gastroenterol 2009, 15:753-755.
- [4]Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR: Use of massively parallel ultra-deep pyro sequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naïve patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol 2009, 83:1718-1726.
- [5]Borroto-Esoda K, Miller MD, Arterburn S: Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepato l 2007, 47:492-498.
- [6]Bartholomeusz A, Locarnini S: Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006, 78(Suppl 1):S52-S55.
- [7]Liu BM, Li T, Xu J, Li XG: Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients. Antiviral Res 2010, 85:512-519.
- [8]Norder H, Couroucé AM, Coursaget P: Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004, 47:289-309.
- [9]Biswas A, Banerjee A, Chandra PK: Variations in the functional domain of basal core promoter of hepatitis B virus among Eastern Indian patients with prevalence of genotypes A, C, and D among the same ethnic population. J MedVirol 2011, 83:253-260.
- [10]Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C, Hepatitis B Virus Drug Resistance Working Group: Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007, 46(1):254-265.
- [11]Datta S, Panigrahi R, Biswas A: Genetic characterization of hepatitis B virus in peripheral blood leukocytes: evidence for selection and compartmentalization of viral variants with the immune escape G145R mutation. J Virol 2009, 83(19):9983-9992.
- [12]Stuyver LJ, Locarnini SA, Lok A: Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001, 33:751-757.
- [13]Warner N, Locarnini S, Kuiper M: The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro Antimicrob. Agents Chemother 2007, 51:2285-2292.
- [14]Svicher V, Gori C, Trignetti M: The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol 2009, 50:461-470.
- [15]Ismail AM, Samuel P, Eapen CE, Kannangai R, Abraham P: Antiviral resistance mutations and genotype-associated amino acid substitutions in treatment-naïve hepatitis B virus-infected individuals from the Indian subcontinent. Intervirology 2012, 55(1):36-44. Epub 2011 Feb 11
- [16]Salpini R, Svicher V, Cento V: Characterization of drug resistance mutations in HBV D genotype chronically infected patients, Naïve to antiviral drugs. Antiviral Res 2011, 92(2):382-385.
- [17]Chandra PK, Biswas A, Datta S: Subgenotypes of hepatitis B virus genotype D (D1, D2, D3 and D5) in India: differential pattern of mutations, liver injury and occult HBV infection. J Viral Hepat 2009, 16(10):749-756.
- [18]Bartholomeusz A, Locarnini SA: Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006, 26:162-170.
PDF